CurveBeam AI Ltd (ASX: CVB) Share Price and News

--

--

Mr Brown has 35 years experience in the healthcare industry, in medical devices (including in vitro diagnostic medical devices) and personalised medicine. Prior to joining CurveBeam, Mr Brown held marketing roles at Baxter Diagnostics (Australia and United Kingdom), Roche Molecular Systems Inc. (Switzerland and U.S.) and Digene Corporation (U.S. and Germany) and was Chief Executive Officer at ImpediMed Limited (ASX:IPD). Until April 2023, Mr Brown was a director of Australian biotechnology company Immunexpress Pty Ltd. He is also a director of an Australian management consulting company, Cintra Consulting Pty Ltd. He has previously served as a director of Trinity Biotech plc (Nasdaq: TRIB), ImpediMed Limited (ASX:IPD), Minomic International Limited and the University of Queenslands commercialisation company, UniQuest Pty Ltd.

--

--

--

--

Ms Robb has over 25 years finance, governance, risk management and compliance experience. Ms Robb commenced her career at PwC and has held senior audit and risk roles at United Energy Limited (ASX:UEL), ANZ Banking Group Limited (ASX:ANZ) and AGL Energy Limited (ASX:AGL). Ms Robb previously served as a non-executive director and chair of the audit committee of unlisted public company Sandringham Community Financial Services Ltd, a Bendigo Bank Community Bank. Ms Robb was appointed to the board of directors of Solvar Limited (formerly Money Corporation Ltd) (ASX:SVR) (SVR) in September 2019. She is also chair of SVRs audit and risk committee and a member of the nominations and remuneration committee over the same time period.

Mr Lilley has over 35 years experience in the medical device and diagnostics industries. Mr Lilley previously served as senior vice president of global sales and marketing for Digene Corporation (Nasdaq:DIGE), a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. (NYSE:QGEN). Mr Lilley is currently the Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company.

Mr Singh has over 34 years experience in the technology industry, with in medical imaging. Since 2009, he has served as President and Chief Executive Officer of CurveBeam US, prior to which Mr Singh co-founded and served as the Vice President and Chief Technology Officer of Imaging Sciences International Inc. (ISI), which was subsequently acquired by Danaher Corporation.

Mr Silva was appointed to the Board of the Company in 2021 as a nominee of Karst Peak Capital Limited (Karst Peak).Mr De Silva Is currently the Founder and Managing Partner of KP Rx, a healthcare fund manager on innovative healthcare companies based in Australia and New Zealand. Previously he held the role of head of healthcare research at Karst Peak, an investment management firm based in Sydney and Hong Kong, which has a focus on biotechnology, health technology, medical devices and diagnostics. Mr De Silva previously served as an equity research analyst in healthcare at CLSA Limited and at Macquarie Group. Mr De Silva was appointed to the board of directors of Pharmaxis Limited (ASX:PXS) in January 2023.

-

-

-